Back

Sergio Ozan

CEPROC Centro Prótesis Oculares y Contactología Especializada, Argentina

Title: JUMAT orbit implant

Biography

Sergio Ozan is an Optician at the University of Buenos Aires, Argentina. He is a Specialist in Contact Lenses, specialist and manufacturer of ocular prosthesis. He is a scientific adviser for ocular prosthesis in APO (Asociación Profesional de Optómetras in Argentina). He is a Precursor and creator of multiperforated orbital implant, JUMAT. He is a Precursor and creator of expander orbit asmotic hydrogel filling for microophthalmia. He is the Director of CEPROC and the Director of Ocular Prosthesis Division in Perfect Vision, Santiago, Chile. He is the Developer of one-hour customized ocular prosthesis method, unique in Latin-America and the Precursor and creator of the first prosthetic sclera lens

Abstract

This implant was created considering the good qualities of previous ones and improving their flaws. To start the fabrication, I looked for material that was easy to get in the market and with low cost. JUMAT is made with hypoallergenic high-density polymethylmethacrylate. It is made in different sizes, from 10 mm to 22 mm. This is really helpful for the surgeon, as he counts with different sizes at the operation theater and can select on site the most suitable one. This is essential for the successful adaptation of the implant. JUMAT orbit implant has multiple perforations of different diameters, being the principal one, the one that marks the implant axis and crosses it completely. This perforation has larger diameter in the back area and smaller in the front one. All other perforations connect with the principal one and interconnect among themselves too. This system of perforations is essential to foster an excellent vascularization. Within ten days of surgery the patient is ready to start with the testing for the adaptation of a prosthethic eye. As from 2010 to present time, 235 JUMAT implants have been implanted with only two expulsions reported. These cases were studied in detail. It was observed that both cases involved children with retinoblastoma. They were enucleated and were implanted with JUMAT. These two children were derived to Children's Garrahan Hospital in Buenos Aires, leading children’s hospital in Argentina. They were under radiotherapy and chemotherapy. These two processes avoided tissue vascularization by necrosia, which determined the expulsion of the implant.

 

 

 

Considering material, cost of material, availability of various implant dimensions, surgeon possibility of choosing exact measure during operation, JUMAT implant proves to be the best option.

 

Statistics

 

The study covers a ten year period, 2000 – 2010, with 316 surgeries.

 

Study field

Age

Cause Eye Loss

implants/ surgeries

Children

1-5

Retinoblastoma

192

Pubers/Teens

8-14

Infections/Accidents

60

Young adult

18-26

Accidents/Tumors/Infections

34

Adult

30-60

Accidents/Glaucoma

30

 

None JUMAT implant expelled. 100% effectiveness

 

Comparison of expulsion

 

Research between 2000 - 2010.

 

Cases

Implant

% expulsion

60

Hydroxyapatite

15

75

Medpor

38

90

PMMA

78

316

JUMAT

0